258,869 Shares in Elanco Animal Health Incorporated (NYSE:ELAN) Bought by Phocas Financial Corp.

Phocas Financial Corp. bought a new position in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 258,869 shares of the company's stock, valued at approximately $3,857,000. Phocas Financial Corp. owned approximately 0.05% of Elanco Animal Health at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the stock. Comerica Bank purchased a new position in shares of Elanco Animal Health in the third quarter worth $40,000. Advisory Services Network LLC raised its stake in shares of Elanco Animal Health by 104.1% in the first quarter. Advisory Services Network LLC now owns 5,204 shares of the company's stock worth $49,000 after purchasing an additional 2,654 shares during the last quarter. Captrust Financial Advisors raised its stake in shares of Elanco Animal Health by 57.0% in the first quarter. Captrust Financial Advisors now owns 2,690 shares of the company's stock worth $70,000 after purchasing an additional 977 shares during the last quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main purchased a new position in shares of Elanco Animal Health in the fourth quarter worth $70,000. Finally, Covestor Ltd raised its stake in shares of Elanco Animal Health by 1,285.1% in the first quarter. Covestor Ltd now owns 2,978 shares of the company's stock worth $78,000 after purchasing an additional 2,763 shares during the last quarter. 97.48% of the stock is owned by institutional investors.

Insider Transactions at Elanco Animal Health

In other Elanco Animal Health news, Director R David Hoover acquired 20,000 shares of the company's stock in a transaction dated Wednesday, March 6th. The stock was purchased at an average price of $16.14 per share, with a total value of $322,800.00. Following the completion of the purchase, the director now directly owns 185,000 shares in the company, valued at approximately $2,985,900. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.64% of the company's stock.

Analysts Set New Price Targets

Several research analysts have recently weighed in on ELAN shares. Morgan Stanley boosted their price target on Elanco Animal Health from $16.00 to $17.00 and gave the stock an "overweight" rating in a research note on Tuesday, February 27th. Barclays upped their price objective on Elanco Animal Health from $18.00 to $19.00 and gave the company an "overweight" rating in a research report on Tuesday, February 27th. TheStreet upgraded Elanco Animal Health from a "d+" rating to a "c-" rating in a research report on Friday, February 23rd. The Goldman Sachs Group upped their price objective on Elanco Animal Health from $12.50 to $14.00 and gave the company a "sell" rating in a research report on Tuesday, February 27th. Finally, Stifel Nicolaus upgraded Elanco Animal Health from a "hold" rating to a "buy" rating and upped their price objective for the company from $13.00 to $20.00 in a research report on Friday, January 5th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $16.71.

Elanco Animal Health Stock Performance

ELAN traded down $0.48 during midday trading on Monday, reaching $13.87. The company had a trading volume of 4,677,678 shares, compared to its average volume of 4,394,154. The company has a quick ratio of 1.35, a current ratio of 2.75 and a debt-to-equity ratio of 0.92. The business has a 50-day moving average of $15.90 and a two-hundred day moving average of $13.60. The company has a market cap of $6.84 billion, a P/E ratio of -5.65, a P/E/G ratio of 1.51 and a beta of 1.29. Elanco Animal Health Incorporated has a 1 year low of $7.88 and a 1 year high of $16.88.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last issued its quarterly earnings results on Monday, February 26th. The company reported $0.08 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.02). The company had revenue of $1.04 billion during the quarter, compared to analysts' expectations of $1 billion. Elanco Animal Health had a positive return on equity of 6.44% and a negative net margin of 27.87%. The business's quarterly revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.19 EPS. As a group, equities research analysts predict that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.